Top 50 Organoid Technology

The startup develops organoid models and oncology drugs to enhance precision medicine in cancer treatment. Their platform provides accurate and efficient tools for tumor research, facilitating the development of targeted therapies.

Forsea utilizes organoid technology to cultivate seafood, specifically targeting endangered species like freshwater eel, to meet the growing demand for sustainable protein sources. This approach enables scalable production that aims for price parity with traditional seafood, addressing the depletion of aquatic ecosystems and the market's unmet needs.

NextBio utilizes organoid technology and molecular diagnostics to create personalized medicine solutions for researchers and consumers. This approach enables precise drug testing and tailored treatment plans, addressing the limitations of traditional one-size-fits-all medical therapies.

Acoustic Bio is developing a high-throughput Organoid-on-a-Chip screening platform that utilizes microfluidics, acoustic technology, and machine learning to automate the screening of patient-derived organoids for drug development. This platform addresses the challenge of generating large-scale, predictive data to enhance the identification of effective therapies for specific patient populations.

Danwang Medical specializes in regenerative medicine and organoid technology, providing a comprehensive organoid biobank and custom model development for various cancers. Their solutions enable pharmaceutical companies to conduct precise drug screening and toxicology evaluations, addressing the need for more effective and personalized cancer treatments.

The startup develops tumor diagnostic products and organoid technologies for cancer treatment, focusing on the creation, storage, and drug screening of organoids. This approach enables precise tumor characterization and personalized therapeutic strategies, improving treatment outcomes for cancer patients.

Celloid develops a specialized 3D cell culture medium that enables quality-controlled long-term cultivation of organoids for research and therapeutic applications. This technology ensures consistent and viable organoid growth, addressing the challenges of maintaining cell viability over extended periods.

Biodimension develops biofabricated human tissues and organoids for drug and cosmetic safety testing, providing a non-animal alternative that yields more relevant human data. Their technology enhances the drug discovery process by offering customized, three-dimensional tissue models that accurately replicate human biological responses.

Known Medicine develops an organoid platform that utilizes machine learning-based sensitivity assays and omics data to analyze cancer cells from patient fluid samples. This technology enables oncologists to identify predictive biomarkers for drug response, facilitating personalized treatment strategies for cancer patients.

This tissue engineering company develops human organoids for drug discovery and clinical trials. They provide disease models, drug screening assays, and "clinical trials in a dish" using living organoid biobanks and standardized protocols, enabling researchers to accelerate drug development and improve patient stratification.

Visienco provides automated solutions for 3D cell culture handling through its Orgadroid platform. This system automatically classifies and transfers organoids of various types, significantly boosting experimental throughput and reproducibility. The platform utilizes AI-driven phenotypic analysis for consistent, real-time organoid selection based on morphology.

Heartbeat Bio develops advanced cardiac organoid screening platforms to accelerate cardiac drug discovery and development. The company utilizes multi-chamber heart organoids to model human heart development and disease states. This technology supports the identification of novel therapeutic targets for conditions like heart failure and inherited heart muscle disorders.

Doppl supplies industry‑standard organoid models for disease modeling and personalized medicine, offering custom model development, toxicity screening, and epithelial fluid transport assays. Their portfolio supports preclinical drug development across oncology, inflammatory, rare, and immuno‑oncology applications. The company also provides a crowd‑sourced bio‑base of donor samples to enable scalable, high‑quality organoid research.

Xilis provides an end‑to‑end platform that generates patient‑derived 3D micro‑organoids (MOS®) preserving tissue heterogeneity for drug testing. The system automates high‑throughput model production, supports modular phenotypic and immune assays, and applies AI‑driven analytics to deliver quantitative efficacy and safety predictions via a secure cloud dashboard. It serves pharmaceutical, biotechnology, CRO and academic customers needing scalable, high‑fidelity preclinical models.

This biotechnology company develops human pluripotent stem cell-derived organoids and cell types for drug discovery and development. Their platform utilizes these "mini-organs" to model human diseases, enabling more efficient and cost-effective therapeutic innovation.

This startup develops organoid and animal models, including heart, blood-brain barrier, and whole-brain organoids, to create precise predictive evaluation systems for drugs and medical devices. Their platform aims to improve the efficacy and precision of treatments for patients.

Neurxstem provides patented human neural organoid platforms that replicate full brain architecture and generate regulator-grade transcriptomic and metabolomic data with 98–99% reproducibility. The models are used by pharmaceutical and diagnostic developers to validate mechanisms of action, discover targets, and create early biomarkers for neurodegenerative, psychiatric, and aging disorders, while also supplying high‑quality multi‑omic datasets for AI‑driven predictive health models. Revenue is generated through licensing of the organoid technology and sale of curated data packages to biotech, pharma, and AI health‑tech firms.

This company develops high-fidelity organoid models and 3D organoid printers that accurately replicate the physiological state of original tissues. Their multi-cell type organoids serve as patient surrogates, providing advanced solutions for drug testing and research.

Epiloid Biotechnology specializes in 3D human brain organoid testing to predict the preclinical efficacy of neurological drugs. By utilizing human-derived organoids, the company addresses the high failure rate and significant costs associated with traditional preclinical models in drug development.

This company develops immunotherapies by utilizing immune organoids and artificial intelligence to design drugs that function effectively in humans from the initial stages. Their platform aims to accelerate drug discovery timelines and reduce development costs by testing candidates in realistic, patient-matched disease models. By integrating human data early, they seek to deliver safer, more effective therapies with fewer side effects across diverse populations.

This startup develops organ-ink-based bioprinting technology for regenerative medicine. Their decellularized extracellular matrix serves as a bio-ink to cultivate various cell lines, including stem cell-derived organoids, creating organ-specific microenvironments for tissue regeneration.

Hooke Bio develops the patent-protected Mera system, a high-throughput screening platform for analyzing 3D microtissues such as spheroids and organoids. This technology aims to reduce reliance on animal models in preclinical drug development by providing biological data that accelerates the drug discovery process.

EmbryoNet AI Technologies provides deep learning services for high-throughput drug screening and toxicology assessments using organoids and embryos. The platform automates phenotypic analysis to rapidly deliver accurate insights into compound effects on biological development. This specialized AI accelerates therapeutic development by identifying novel compounds and predicting adverse effects early in the research pipeline.

Biond develops organ-on-chip microchips that recreate key aspects of human organs, enabling researchers to nourish, stimulate, and monitor complex 3D tissues for biomedical studies. This technology provides a viable alternative to animal testing, facilitating drug discovery and development while addressing the limitations of traditional research methods.

Mogengel supplies specialized reagents and consumables for 3D cell culture and organoid development. They offer a range of matrix gels and organoid culture media tailored for various cell types and research applications, ensuring consistency and advancing regenerative medicine and disease modeling.

The startup provides biotechnology products and research services for 3D cell, tissue, and organoid culture, utilizing pharmaceutical-grade materials that maintain the bioactivity of natural extracellular matrices. This enables animal-free drug discovery and development, offering a more ethical approach to pharmaceutical research while ensuring mechanical tunability and reproducibility.

Puheng Biomedicine develops in vitro 3D organ and disease models using its proprietary NAC-Organ technology, which enables rapid, high-throughput production of complex humanized models for chronic diseases and tumors. This technology addresses the inefficiencies in drug research and development by providing accurate and standardized platforms for drug screening and testing.

Convo Advanced Manufacturing utilizes acoustic field assembly technology to manipulate cells for the precise construction of functional tissues and organ mimetics. This platform addresses the challenges of traditional biomanufacturing by enabling the creation of complex, three-dimensional structures that closely resemble natural organs, facilitating advancements in regenerative medicine and drug testing.

faCellitate develops polymeric coatings that modify labware surfaces to create inert, cell-repellent environments for advanced cell culture. Their BIOFLOAT™ technology enables the reproducible formation of consistent spheroids and organoids for 3D cell culture applications. The company also offers BIOINSTRUCT™ coatings optimized for defined, xeno-free stem cell expansion.

Orakl Oncology utilizes an AI-native predictive platform integrating patient-derived biology and real-world data to advance oncology drug development. This platform uncovers novel drug targets and accurately predicts patient responses to streamline discovery and clinical translation. The company partners with pharmaceutical firms to de-risk clinical trials, improve R&D efficiency, and accelerate the delivery of new therapeutic options to cancer patients.

Qkine develops and manufactures high-quality, animal-free growth factor proteins specifically for stem cell, organoid, and cellular agriculture applications, ensuring consistent bioactivity through rigorous quality control. Their products address the need for reproducible and reliable biological materials in research and industry, enhancing scientific outcomes across various fields.

Title: Stem Cell Research & Organ-on-chip | NORGANOID GmbH URL Source: http://norganoid.com/ Published Time: 2024-06-08T13:19:24+02:00 Markdown Content: We envision organoid biology and medicine as the future of personalized healthcare, enabling us to discover the most effective treatments for each patient and pioneering organ replacement technologies. By streamlining the creation of these advanced 3D structures, we are accelerating the transition to a new era of patient-focused preclinical e

Systemic Bio develops vascularized organ models using hydrogels and human cells, enabling more accurate preclinical drug testing. Their proprietary 3D Systems technology offers significantly larger build volumes and higher resolution than existing methods, facilitating the creation of customizable organ-on-chip systems for drug discovery.

MBD specializes in 3D cell culture platforms, providing advanced tools for precision medicine and drug development. Their Cellvitro® technology enables more accurate testing of drug efficacy and sensitivity, addressing the limitations of traditional 2D cell cultures in biomedical research.

Mosaic Neuroscience provides an open, cloud‑based platform that combines AI‑driven molecular subtype discovery with patient‑derived iPSC and organoid models for neurodegenerative diseases. The system integrates a disease‑specific knowledge graph and automated drug‑testing workflows, enabling researchers to screen compounds across heterogeneous disease subtypes and generate subtype‑specific efficacy data. Access is offered via subscription, model licensing, and open APIs, with revenues reinvested to expand the infrastructure.

Cellbox Labs develops vascularized organ-on-chip technology that enables pharmaceutical companies to conduct preclinical drug tests using human-like micro-physiological systems. This platform combines hardware and software to facilitate flexible experimental designs while significantly reducing hands-on time in drug discovery processes.

This company develops organ-on-chip devices and assays for drug discovery and diagnostics. They provide products like chip devices for invasion and chemotaxis, alongside CRO services for assessing cell-cell interactions in 3D cell culture using their chip, enhanced by AI-based image analysis for quantitative assessment.

CytoTronics develops the Pixel™ system, which utilizes a semiconductor-to-live-cell interface to provide high-resolution, multiplexed measurements of live cell behavior across various applications. This technology enables researchers to conduct large-scale experiments and gain deeper insights into cell viability, morphology, and metabolism, addressing the limitations of traditional cell biology methods.

Newcells Biotech specializes in developing induced pluripotent stem cell-derived in vitro models for drug discovery, focusing on human tissue simulations such as retinal, kidney, and lung models. Their services provide critical data on drug efficacy and safety, enhancing the predictive accuracy of pre-clinical studies and facilitating clinical translation.

Criocore provides an automated 3D bioprinting platform that creates human tissue constructs for preclinical drug efficacy and toxicity testing. The scalable, physiologically relevant models integrate with standard assay formats, enabling pharmaceutical and biotech firms to replace animal studies with high‑throughput, human‑relevant data.

NextVivo develops 3D immune organoid models that retain key immune cell types and functional interactions for drug development. These human-derived models allow for the generation and testing of safer, more effective cell and antibody therapies. The technology recapitulates primary immune defense mechanisms to address diseases like cancer, infections, and autoimmune disorders.

BrainZell develops stem cell-based models of the human brain for drug discovery and neurological research. These advanced models offer a more accurate representation of human brain function compared to traditional animal models, accelerating the development of new therapies for neurological disorders.

AlveoliX offers organs-on-chip technology that recreates human organ micro-environments for more predictive preclinical drug testing. Their microfluidic systems enable assessment of drug safety, efficacy, and toxicity with greater human relevance, reducing late-stage failures in drug development.

Genenet Technology develops proprietary gene circuit designs by integrating deep learning algorithms to mimic artificial neural networks. This novel biocomputing method enables advanced control over gene expression for applications in synthetic biology and bioproduction. The company provides genetic circuit design services, R&D consultation, and technology licensing for drug discovery, cell and gene therapy, and organoid-on-chip research.

Rosebud Biosciences develops targeted therapies for rare pediatric genetic diseases using patient-specific organoid models. The company engineers micropatterned 2.5D organoids from induced pluripotent stem cells that replicate individual genetic mutations for drug screening. This platform enables the high-throughput testing of small molecules, gene therapies, and RNA therapeutics against complex developmental disorders.

Rosebud Biosciences develops targeted therapies for rare genetic diseases in children by utilizing organoids that replicate the child's specific genetic mutations. This approach enables the screening of potential drug treatments in a human-like model, addressing the significant lack of approved therapies for 95% of these conditions.

Organoid Sciences specializes in organoid-based drug discovery and regenerative medicine, utilizing 3D cultured stem cells to create miniaturized organs that closely mimic human tissue. The company addresses the challenge of organ shortages and the need for personalized treatment options for incurable diseases through its advanced drug screening and regenerative therapeutic platforms.

The startup has developed a three-dimensional humanized adipose tissue model system for in vitro drug discovery, enabling precise disease modeling and cell assays. This technology allows researchers to efficiently identify effective drug compounds for obesity, diabetes, and related metabolic diseases, significantly reducing the time and costs associated with traditional testing methods.

Paitent on Chips develops microfluidic "organ-on-a-chip" systems that simulate human organ functions for drug discovery and development. These platforms enable researchers to test drug efficacy and toxicity in a more physiologically relevant environment than traditional cell cultures, accelerating preclinical research.

Cell Microsystems provides modular, automated instrumentation for high‑throughput single‑cell isolation, culture, and functional analysis. Its CellRaft AIR® platform uses proprietary micro‑raft arrays with label‑free brightfield/fluorescence imaging to identify and robotically retrieve viable cells or colonies, achieving 10–50× higher clonal outgrowth, while complementary sorter, shear‑flow chambers, 3D perfusion bioreactors, and automated patch‑clamp systems deliver end‑to‑end solutions for gene‑editing, organoid work, and electrophysiology assays.